HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: db06-1653v1 56/5/1289    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Emamaullee, J. A. Articles by Shapiro, A.M. J. Search for Related Content PubMed PubMed Citation Articles by Emamaullee, J. A. Articles by Shapiro, A.M. J. Social Bookmarking                What's this?

Caspase Inhibitor Therapy Enhances Marginal Mass Islet Graft Survival and Preserves Long-Term Function in Islet Transplantation

¹ Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
² Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada

Address correspondence and reprint requests to Juliet Emamaullee, PhD, 1074 Dentistry-Pharmacy Centre, Surgical Medical Research Institute, University of Alberta, Edmonton, AB T6G 2N8, Canada. E-mail: juliete{at}ualberta.ca

Abbreviations: AUC, area under the curve; DAPI, 4'6-diamidino-2-phenylindole; IPGTT, intraperitoneal glucose tolerance test; STZ, streptozotocin; TUNEL, transferase-mediated dUTP nick-end labeling; zVAD-FMK, N-benzyloxycabonyl-Val-Ala-Asp-fluoromethyl ketone

Islet transplantation can provide insulin independence in patients with type 1 diabetes, but islets derived from two or more donors are often required. A significant fraction of the functional islet mass is lost to apoptosis in the immediate posttransplant period. The caspase inhibitor N-benzyloxycabonyl-Val-Ala-Asp-fluoromethyl ketone (zVAD-FMK) has been used therapeutically to prevent apoptosis in experimental animal models of ischemic injury, autoimmunity, and degenerative disease. In the current study, zVAD-FMK therapy was examined in a syngeneic islet transplant model to determine whether caspase inhibition could improve survival of transplanted islets. zVAD-FMK therapy significantly improved marginal islet mass function in renal subcapsular transplantation, where 90% of zVAD-FMK–treated mice became euglycemic with 250 islets, versus 27% of the control animals (P < 0.001). The benefit of zVAD-FMK therapy was further demonstrated after intraportal transplantation, where 75% of zVAD-FMK–treated animals established euglycemia with only 500 islets, and all of the controls remained severely diabetic (P < 0.001). zVAD-FMK pretreatment of isolated islets in the absence of systemic therapy resulted in no significant benefit compared with controls. Long-term follow-up of transplanted animals beyond 1 year posttransplant using glucose tolerance tests confirmed that a short course of zVAD-FMK therapy could prevent metabolic dysfunction of islet grafts over time. In addition, short-term zVAD-FMK treatment significantly reduced posttransplant apoptosis in islet grafts and resulted in preservation of graft insulin reserve over time. Our data suggest that caspase inhibitor therapy will reduce the islet mass required in clinical islet transplantation, perhaps to a level that would routinely allow for insulin independence after single-donor infusion.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. A. Emamaullee, J. Davis, R. Pawlick, C. Toso, S. Merani, S.-X. Cai, B. Tseng, and A.M. J. Shapiro The Caspase Selective Inhibitor EP1013 Augments Human Islet Graft Function and Longevity in Marginal Mass Islet Transplantation in Mice Diabetes, June 1, 2008; 57(6): 1556 - 1566. [Abstract] [Full Text] [PDF]

				R. Granata, F. Settanni, D. Gallo, L. Trovato, L. Biancone, V. Cantaluppi, R. Nano, M. Annunziata, P. Campiglia, E. Arnoletti, et al. Obestatin Promotes Survival of Pancreatic {beta}-Cells and Human Islets and Induces Expression of Genes Involved in the Regulation of {beta}-Cell Mass and Function Diabetes, April 1, 2008; 57(4): 967 - 979. [Abstract] [Full Text] [PDF]